Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek, taking place from November 3-6, 2024 in San Antonio, TX.
舊金山，2024年10月31日/全球新聞社/ -- Structure Therapeutics Inc.（納斯達克股票代碼：GPCR），一家臨床階段的全球生物製藥公司，專注於開發用於代謝和肺部疾病的新型口服小分子藥物治療方案，今天宣佈將在2024年11月3日至6日於德克薩斯州聖安東尼奧舉行的肥胖學會年會ObesityWeek上展示多個即將發佈的海報。
Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity Treatment
Poster Number: Poster 128
Date/Time: Sunday, November 3, 7:30 p.m. – 8:30 p.m. CT
Location: Exhibit Hall 4
標題: 用於肥胖治療的新型口服小分子雙阿米林和降鈣素受體激動劑
海報編號: 海報128
日期/時間: 2024年11月3日星期日，晚上7:30點 – 8:30點中部時間
地點: 4號展廳
Title: Drug Design Principles and Pharmacokinetics/Pharmacodynamics of GSBR-1290, a Small Molecule GLP-1RA
Poster Number: Poster 337
Date/Time: Monday, November 4, 2:30 p.m. – 3:30 p.m. CT
Location: Exhibit Hall 4
標題: GSBR-1290的藥物設計原則和藥代動力學/藥效動力學，一種小分子GLP-1RA
海報編號：海報337
日期/時間：週一，11月4日，下午2:30至3:30中部時間
地點：展廳4
Title: Significant and Clinically Relevant Weight Changes at 12 Weeks with Small Molecule GLP-1RA, GSBR-1290
Poster Number: Poster 342
Date/Time: Monday, November 4, 2:30 p.m. – 3:30 p.m. CT
Location: Exhibit Hall 4
標題：小分子GLP-1RA，GSBR-1290在12周時的重要且臨床相關的體重變化
海報編號：海報342
日期/時間：週一，11月4日，下午2:30至3:30中部時間
地點：展廳4
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit .
關於Structure Therapeutics
Structure Therapeutics是一家以科學爲驅動的臨床階段生物製藥公司，專注於發現和開發創新的口服小分子治療方法，用於治療慢性代謝和心肺疾病，滿足醫療領域迫切需求。憑藉其下一代基於結構的藥物發現平台，該公司建立了一個強大的靶向GPCR的管線，擁有多個自有的臨床階段小分子化合物，旨在超越傳統生物製劑和肽治療的可擴展性限制，併爲全球更多患者提供服務。欲了解更多信息，請訪問。
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
投資者：
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
媒體：
Dan Budwick
1AB
Dan@1abmedia.com
譯文內容由第三人軟體翻譯。
